Difference between revisions of "Team:NCKU Tainan/Entrepreneurship"

Line 351: Line 351:
 
});  
 
});  
 
</script>  
 
</script>  
  <script>
+
<script src="https://2019.igem.org/Team:NCKU_Tainan/js/publicEngagement?action=raw&ctype=text/javascript"></script>
  $( document ).ready(function() {
+
       
    $("#breadtext").html('<a href="https://2019.igem.org/Team:NCKU_Tainan/Human_Practices">HP</a> > <a>Public Engagement</a>')
+
  });
+
</script>      
+
 
</body>
 
</body>
 
</html>
 
</html>
 
{{Template:NCKU_Tainan/gotop}}   
 
{{Template:NCKU_Tainan/gotop}}   
 
{{Template:NCKU_Tainan/footer}}
 
{{Template:NCKU_Tainan/footer}}

Revision as of 05:39, 17 October 2021


Collab

Overview

This year, iGEM NCKU Tainan is focusing on therapeutics. Our Oh My Gut project aims to tackle a problem which is still unknown to many people. We are using synthetic biology to create a comprehensive solution to solve the problem of p-Cresol accumulation in CKD patients, to reduce the risks of getting cardiovascular diseases or other serious complications and help them achieve a better quality of life. We wanted to realize our project from the laboratory and apply it in the real market. Oh My Gut provides solutions to improve the quality of lives of people by setting up an affordable healthcare platform to increase the accessibility to anyone who requires medical advice, attention and products.

To bring our vision and mission into reality, engaging with our customers and stakeholders is crucial. We started with mapping out our target users, which are CKD patients and stakeholders. At first, we proposed that our engineered E. coli Nissle 1917 that possesses the ability to reduce p-Cresol accumulation can be marketed as a probiotic. However, after discussing with Taiwan Food and Drug Administration, we realized that because our product contains pharmacological effects, we need to market it as a drug. Therefore, we decided on marketing our product as a living therapeutic drug called CreSolve. Aside from a living therapeutic drug, we also designed CreSense, a medical device to help measure blood p-Cresol level using our engineered p-Cresol sensing bacteria.

We are very proud that our Oh My Gut project is able to evolve into CreSolve and CreSense which despite being two different products with different business models, all fall under one same goal. CreSolve living therapeutic drug will be directly sold to our distributors, while CreSense will be leased out to healthcare platforms and apply a recurring revenue business model to the suppliance of bacteria refills and microfluidic disc.

In order to understand how therapeutic drugs and medical devices can enter the real market, we started at the bottom, discussing the value proposition of the products and understanding customer’s needs. We subsequently conducted market and competitor research, thoughtfully devise our business model, and wrote our business plan. We aim to interpret the value of our products into a commercial business.

WHAT WE HAVE?

consideration

Mission & Vision

 Assesment and evaluations of the things needed in order to potentially develop CreSense and CreSolve into a mature product.

design

Visualize-Design-Test

 Identification and analysis of the values of CreSense and CreSolve through the help of a business model to support the viability of our products.

business

Product Value

 A detailed plan of the strategies and processes of realizing CreSolve and CreSense’s vision and objectives.

consideration

Interview Insights

 Assesment and evaluations of the things needed in order to potentially develop CreSense and CreSolve into a mature product.

design

FITI

 Identification and analysis of the values of CreSense and CreSolve through the help of a business model to support the viability of our products.

business

Future

 A detailed plan of the strategies and processes of realizing CreSolve and CreSense’s vision and objectives.






Mission & Vision


 Our mission is to develop and distribute a novel and effective solution to combating stress-induced depression by integrating it within bubble milk tea.

 Our vision is to become a focal company leading the modernized bubble industry possessing health-beneficial functional products.

Visualize-Design-Test


Business Model Canvas:
business
Competition Analysis
business
SWOT Analysis
business

Product Value


business

Interview Insights


Trade wind biotech

Trade Wind Biotech (TWBIO) is a pioneer company based in Taiwan that implements synthetic biology as its core technique. We were allowed to visit their factory and laboratory led by Dr Lance, the CEO of TWBIO. We also invited team CCU_Taiwan to join us on this trip, and both of our teams received a lot of feedback from Dr Lance regarding entrepreneurship and presentation skills.

Chen En Food Product Enterprise Co., Ltd

Our team was honoured to interview the general manager of Chen En Food Product Enterprise, Mr Vincent, as Chen En is one of the largest bubble suppliers in both local and global markets. Before the online interview session began, we signed a Memorandum of Understanding (MOU) with them. As a giant bubble supplier, they provided advice on preparing our bubble with the engineered bacteria inside. In addition, they also gave us valuable market data to further our business model.

genemont

8D Tea Fresh Kitchen

We visited a local handmade bubble tea shop in Nantou and their IoT live kitchen to learn more about bubble production and marketing. They also suggested we market our product as chilled ready-to-eat (RTE) food, allowing us to position it in the market correctly. We also witnessed how they made bubbles from scratch and learned of the sterilization and bubble heating process. For more details, please click on the file below!

FITI


From IP to IPO Program (FITI) is a startup business competition in Taiwan on information communication, biology, medicine, science, and technology. In this competition, we were required to submit a 20-slide presentation showing the business plan for our startup. During the preparation, FITI provided an advisor, Ms. Peggy Chen, who clarified the competition's guidelines. Furthermore, through this competition, we met with our team consultant Dr. Lance Chang, the First Grand Winner of the FITI competition, and the CEO of Trade Wind Biotech. Gaining support and assistance has been especially helpful for us when conducting our business plan, especially in developing our marketing strategy.

Future


In the future, complying with Taiwan's food safety regulations will be our top priority. After our research is completed, we aim to distribute our product to be authorized by the government. Only when this step is completed will we move forward with our business plan. We have designed two areas of products for humans and pets according to our three-generation business plan. Apart from profit, we hope to build a sustainable project and provide more job opportunities in Taiwan and worldwide.

Reference

  1. Tsai, Ming-Hsien, et al, “Incidence, Prevalence, and Duration of Chronic Kidney Disease in Taiwan: Results from a Community-Based Screening Program of 106,094 Individuals.” Nephron, vol. 140, no. 3, 2018, pp. 175–184, www.ncbi.nlm.nih.gov/pubmed/30138926, 10.1159/000491708.
  2. Michishita, Ryoma, et al. “The Association between Changes in Lifestyle Behaviors and the Incidence of Chronic Kidney Disease (CKD) in Middle-Aged and Older Men.” Journal of Epidemiology, vol. 27, no. 8, Aug. 2017, pp. 389–397, 10.1016/j.je.2016.08.013.
  3. Jha, V, and G Garcia-Garcia. “Chronic Kidney Disease in Disadvantaged Populations.” Indian Journal of Nephrology, vol. 25, no. 2, 2015, p. 65, www.ncbi.nlm.nih.gov/pmc/articles/PMC4379627/, 10.4103/0971-4065.150078
  4. “1 in 10 People Worldwide Have CKD, but Many Governments Don’t Make Kidney Disease a Priority.” Healio.Com, 2018, www.healio.com/nephrology/chronic-kidney-disease/news/online/%7B7e9674fe-121f-4ec3-a62a-089b73108ffe%7D/1-in-10-people-worldwide-have-ckd-but-many-governments-dont-make-kidney-disease-a-priority.
  5. THE HIDDEN EPIDEMIC: WORLDWIDE, OVER 850 MILLION PEOPLE SUFFER FROM KIDNEY DISEASES. 2018.
  6. “KREMEZIN / COVALZIN | KUREHA CORPORATION.” ​Kureha.Co.Jp,​ 2014,